- Home
- EVG vs UNCY Comparison
EVG vs UNCY Comparison
Compare EVG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EVG
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EVG | UNCY |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 126.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVG | UNCY |
|---|---|---|
| Price | $10.99 | $6.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 49.4K | ★ 394.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $3.71 |
| 52 Week High | $10.86 | $11.00 |
Technical Indicators
Market Signals| Indicator | EVG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 61.59 |
| Support Level | $10.96 | $5.65 |
| Resistance Level | $11.09 | $5.95 |
| Average True Range (ATR) | 0.07 | 0.42 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 72.00 | 92.31 |
Price Performance
Historical ComparisonAbout EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.